Chunk #12 — 3. RESULTS — 3.1 CHRNA5 and pharmacotherapy are associated with abstinence — 3.1.1 UW-TTURC Trial (N=328)

Source

Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.

Embedded

yes

Text

Table S11 shows demographics and genotype frequencies. 48.5% of participants were abstinent at EOT (8 weeks post-quit). Receiving cNRT, compared to placebo, increased abstinence (60.1% in cNRT n =193; 31.9% in placebo n =135; OR=3.17, 95% CI=1.99–5.05, df=1, p= 8.1×10−6).